

Published on *UCSF Department of Radiation Oncology* (<https://radonc.ucsf.edu>)

[Home](#) > [Our Team](#) > [Medical Faculty](#) > [Mack Roach](#)

Mack Roach

Mack Roach III, M.D., F.A.C.R.



Professor

Departments of Radiation Oncology & Urology

University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
Box 1708, 1600 Divisadero St, H1031
San Francisco, CA 94115
Phone: (415) 353-9860
Fax: (415) 353-9883
Email: [mack.roach\[at\]ucsf.edu](mailto:mack.roach[at]ucsf.edu)

Make A Gift
Support Our Research

[1]

Professional Focus

Dr. Roach is a Professor of Radiation Oncology and Urology in the Department of Radiation Oncology at the University of California San Francisco. He is recognized as a major authority on the treatment of localized prostate cancer. His research interests involve the application of image-guided intensity-modulated radiation therapy (IMRT) and Brachytherapy and defining the optimal imaging modalities and criteria for selecting specific targets for radiation, while minimizing treatment related complications. He has helped to pioneer the use of endorectal Magnetic Spectroscopy imaging as a means of monitoring prostate cancer outcomes. Dr.

Roach was a leader in establishing the American College of Radiology (ACR) Appropriateness Criteria Guidelines for defining how men with prostate cancer should be treated with radiotherapy from 1996 through 2006. He also served on the NCI Intensity Modulated Radiotherapy Working Group describing criteria for the use of this new technology and currently serves on the National Comprehensive Cancer Guidelines Committee for Prostate Cancer. He has been the recipient of numerous awards, such as the American Cancer Society Career Development Award and the UCSF Health Net Wellness Award. He is a Fellow of the ACR and ASTRO. Dr. Roach has co-authored more than 200 peer-reviewed journal articles, book chapters and/or editorials. He has served on numerous editorial boards and was appointed (2013) by President Obama to serve on a 6-year term on the National Cancer Advisory Board (NCAB) which is involved in defining the research agenda for our nation. He has lead two large Phase III Trials evaluating the role of whole-pelvic radiation in men with high risk prostate cancer, and when completed in total, nearly 4000 men will have been enrolled on these two studies. A major research interest of his work has been to reduce the risk of erectile dysfunction (and other side-effects) associated with treatment of prostate cancer with radiation. He is currently also very active in the efforts to develop the capacity to harness heavy charged particles for the treatment of radiation resistant cancers.

Education

1975	Morehouse College, Atlanta, GA	BS (Honors)	Physics
1979	Stanford University School of Medicine	MD	
1979-1981	Martin Luther King, Jr., General Hospital, Los Angeles, CA	Internship and Resident	
1981-1983	UCSF	Fellow	Hematology-Oncology
1983-1984	Highland General Hospital, Oakland, CA	Chief Resident	Medicine
1984-1987	Stanford University School of Medicine	Resident	Radiation Therapy (Chief Resident - 1986)

Professional Experience

2014-present	UCSF	Professor	Radiation Oncology
2007-2014	UCSF	Professor & Chair	Radiation Oncology
2006-2007	UCSF	Professor & Interim Chair	Radiation Oncology
2003-2006	UCSF	Professor & Vice Chair	Radiation Oncology
2003-present	UCSF	Professor	Urology

2001-present	UCSF	Director, Clinical Research	Radiation Oncology
2000-2003	UCSF	Professor in Residence	Radiation Oncology & Urology
1997-2000	UCSF	Associate Professor	Urology
1994-2000	UCSF	Associate Professor in Residence	Radiation Oncology & Medical Oncology
1990-1994	UCSF	Assistant Professor in Residence	Radiation Oncology
1988-1990	Veterans Administration Medical Center, Martinez, CA	Chief	Radiation Oncology
Services			
1987-1988	Veterans Administration Medical Center, Martinez, CA	Acting Chief	Radiation Oncology Services

Awards & Honors

1979-1980	Outstanding Intern of the Year (Charles R. Drew Award)
1981-1982	Fellow, American Cancer Society
1994-1997	American Cancer Society, Career Development Award
1994	UCSF Health Net Wellness Award
1996-1997	Best Doctors in America ®
1997, 1998	Best Doctors in the Bay Area
1999	Health & Wellness Award - 100 Black Men of the Bay Area Inc.
2001-2002	Best Doctors in America ®
2002	Fellow, American College of Radiology
2002-2003	President, John Hale Medical Society
2003-2004	Best Doctors in America ®
2005	10 Most Influential African Americans in the Bay Area (Healthcare)
2005-2006	Best Doctors in America ®
2007	UCSF Award for Community Service
2007-2008	The Best Doctors in America ®
2008	Bennie Service Award, Morehouse College

Recent Significant Publications :

Kaidar-Person O, Roach M 3rd, Créhange G. **Whole-Pelvic Nodal Radiation Therapy in the Context of Hypofractionation for High-Risk Prostate Cancer Patients: A Step Forward.** Int J Radiat Oncol Biol Phys. 2013 Mar 19.

Chang AJ, Roach M 3rd. **Cautious Optimism for Extreme Dose Escalation in Prostate Cancer.** Eur Urol. 2013 Feb 28.

Cury FL, Hunt D, Roach M 3rd, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C. **Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413.** Cancer. 2013 Mar 15.

Chen CP, Weinberg V, Shinohara K, Roach M 3rd, Nash M, Gottschalk A, Chang AJ, Hsu IC. **Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes.** Int J Radiat Oncol Biol Phys. 2013 Mar 5.

Roach M 3rd, Thomas K. **Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?** J Natl Cancer Inst Monogr. 2012 Dec;2012(45):221-9.

Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strobe SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. **Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines** J Natl Compr Canc Netw. 2012 Sep;10(9):1081-7.

Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M 3rd. **Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.** Cancer Treat Rev. 2012 Dec;38(8):956-67.

Roach M 3rd. **Long-term potency preservation following brachytherapy for prostate cancer.** BJU Int. 2012 Jul;110(2):225.

Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M 3rd. **Management of prostate cancer patients with lymph node involvement: A rapidly evolving paradigm.** Cancer Treat Rev. 2012 Jun 13.

Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M 3rd. **Feasibility of MR Imaging/MR Spectroscopy-Planned Focal Partial Salvage Permanent Prostate Implant (PPI) for Localized Recurrent After Initial PPI for Prostate Cancer.** Int J Radiat Oncol Biol Phys. 2012 Jun 4.

Source URL: <https://radonc.ucsf.edu/mack-roach>

Links

[1] <https://radonc.ucsf.edu/make-gift>